How much funding has Vigil Neuroscience raised?

Vigil Neuroscience has raised $140.0M in total funding, most recently a Series B round.

Who are Vigil Neuroscience's investors?

Vigil Neuroscience's investors include Atlas Venture, Vida Ventures, Amgen, Pivotal Life Sciences.

When was Vigil Neuroscience founded?

Vigil Neuroscience was founded in 2020.

Where is Vigil Neuroscience headquartered?

Vigil Neuroscience is headquartered in Cambridge, Massachusetts, United States.

What industry is Vigil Neuroscience in?

Vigil Neuroscience operates in Biotech, Healthcare.

How many employees does Vigil Neuroscience have?

Vigil Neuroscience has 11-50 employees.

Vigil Neuroscience

Closed

Cambridge, United States · Founded 2020 · $140.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: vigilneuro.com
Total Funding: $140.0M
Last Round: $90.0M Series BAug 2021
Rounds: 2

About

Vigil Neuroscience was a biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, focused on harnessing the power of microglia to develop treatments for neurodegenerative diseases. The company pipeline centered on TREM2 (Triggering Receptor Expressed on Myeloid cells 2), a key receptor that regulates microglial function in the brain, with both antibody and small molecule agonist programs targeting neuroinflammation in Alzheimer disease, rare leukodystrophies, and other CNS conditions. Vigil lead programs included VGL101, an anti-TREM2 antibody for CSF1R-related leukodystrophy, and VG-3927, a novel oral small molecule TREM2 agonist. The company raised $140 million in financing before being acquired by Sanofi in 2025 for $470 million, adding its investigational TREM2 agonist to Sanofi neurology pipeline.

Summary

Vigil Neuroscience is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $140.0M in total across 2 rounds, most recently a $90.0M Series B round in Aug 2021. Investors include Atlas Venture, Vida Ventures and Amgen.